[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 201, "companyOfficers": [{"maxAge": 1, "name": "Dr. John F. Milligan Ph.D.", "age": 62, "title": "Executive Chairman", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 150000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David H. Kirn M.D.", "age": 60, "title": "Co-Founder, CEO & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 1008093, "exercisedValue": 0, "unexercisedValue": 308925}, {"maxAge": 1, "name": "Dr. Fariborz  Kamal Ph.D.", "age": 60, "title": "President & COO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 786201, "exercisedValue": 0, "unexercisedValue": 3869287}, {"maxAge": 1, "name": "Dr. Noriyuki  Kasahara M.D., Ph.D.", "age": 60, "title": "Chief Scientific Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 201288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Y. Kim M.B.A., M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 704843, "exercisedValue": 0, "unexercisedValue": 567555}, {"maxAge": 1, "name": "Ms. Theresa  Janke", "age": 48, "title": "Co-Founder & Chief of Staff", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 652315, "exercisedValue": 0, "unexercisedValue": 703125}, {"maxAge": 1, "name": "Mr. Uneek  Mehra", "age": 51, "title": "Chief Financial & Business Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Scott P. Bizily J.D., Ph.D.", "age": 50, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. An  Song Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.", "age": 62, "title": "Senior VP & Therapeutic Area Head of Pulmonology", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.41, "open": 10.32, "dayLow": 10.1009, "dayHigh": 10.41, "regularMarketPreviousClose": 10.41, "regularMarketOpen": 10.32, "regularMarketDayLow": 10.1009, "regularMarketDayHigh": 10.41, "beta": 2.793, "forwardPE": -3.1215808, "volume": 1014273, "regularMarketVolume": 1014273, "averageVolume": 1012439, "averageVolume10days": 1684160, "averageDailyVolume10Day": 1684160, "bid": 10.18, "ask": 10.27, "bidSize": 100, "askSize": 100, "marketCap": 541003072, "fiftyTwoWeekLow": 9.44, "fiftyTwoWeekHigh": 36.25, "priceToSalesTrailing12Months": 26.758486, "fiftyDayAverage": 14.8402, "twoHundredDayAverage": 22.09975, "currency": "USD", "enterpriseValue": 5437689, "floatShares": 26397434, "sharesOutstanding": 51969600, "sharesShort": 9517746, "sharesShortPriorMonth": 9953253, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.1831, "heldPercentInsiders": 0.0348, "heldPercentInstitutions": 1.12503, "shortRatio": 21.52, "shortPercentOfFloat": 0.18969999, "impliedSharesOutstanding": 52678000, "bookValue": 11.333, "priceToBook": 0.90620315, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -109893000, "trailingEps": -2.24, "forwardEps": -3.29, "pegRatio": 0.25, "enterpriseToRevenue": 0.269, "enterpriseToEbitda": -0.043, "52WeekChange": -0.16504067, "SandP52WeekChange": 0.34083736, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FDMT", "underlyingSymbol": "FDMT", "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "firstTradeDateEpochUtc": 1607697000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3c71667a-4f1e-3d28-8cb0-26ab7aa9e925", "messageBoardId": "finmb_272879653", "gmtOffSetMilliseconds": -14400000, "currentPrice": 10.27, "targetHighPrice": 82.0, "targetLowPrice": 36.0, "targetMeanPrice": 50.0, "targetMedianPrice": 42.5, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 541945984, "totalCashPerShare": 10.428, "ebitda": -126755000, "totalDebt": 13656000, "quickRatio": 27.931, "currentRatio": 28.482, "totalRevenue": 20218000, "debtToEquity": 2.321, "revenuePerShare": 0.426, "returnOnAssets": -0.16864, "returnOnEquity": -0.24059999, "freeCashflow": -52979248, "operatingCashflow": -85152000, "revenueGrowth": -0.979, "operatingMargins": -8491.2, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]